Immunological aspects of cancer chemotherapy

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399

Calreticulin exposure dictates the immunogenicity of cancer cell death

Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896

Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473

A cytokine-mediated link between innate immunity, inflammation, and cancer

Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737

Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512

Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity

Shimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491

Cell-Surface Calreticulin Initiates Clearance of Viable or Apoptotic Cells through trans-Activation of LRP on the Phagocyte

Gardai, S. J., McPhillips, K. A., Frasch, S. C., Janssen, W. J., Starefeldt, A., Murphy-Ullrich, J. E., Bratton, D. L., Oldenborg, P.-A., Michalak, M., & Henson, P. M. (2005) · Cell · doi:10.1016/j.cell.2005.08.032 · Cited by 1,473

Cancer despite immunosurveillance: immunoselection and immunosubversion

Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

Gasser, S., Orsulic, S., Brown, E. J., & Raulet, D. H. (2005) · Nature · doi:10.1038/nature03884 · Cited by 1,308

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, É., Cesne, A. L., Zitvogel, L., & Chauffert, B. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,285

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells

Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,073

Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo

Fernandez, N. C., Lozier, A., Flament, C., Ricciardi‐Castagnoli, P., Bellet, D. H., Suter, M., Perricaudet, M., Tursz, T., Maraskovsky, E., & Zitvogel, L. (1999) · Nature Medicine · doi:10.1038/7403 · Cited by 1,057

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

Ghiringhelli, F., Menard, C., Terme, M., Flament, C., Taı̈eb, J., Chaput, N., Puig, P. E., Novault, S., Escudier, B. J., Vivier, É., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051511 · Cited by 1,004

Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor

Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

Lutsiak, M. E. C., Semnani, R. T., De Pascalis, R., Kashmiri, S. V. S., Schlom, J., & Sabzevari, H. (2005) · Blood · doi:10.1182/blood-2004-06-2410 · Cited by 903

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

Ghiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B., Solary, É., Bonnotte, B., & Martin, F. (2004) · European Journal of Immunology · doi:10.1002/eji.200324181 · Cited by 878

Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis

Weinblatt, M. E., Coblyn, J. S., Fox, D. A., Fraser, P. A., Holdsworth, D. E., Glass, D. N., & Trentham, D. E. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503283121303 · Cited by 872

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death

Kroemer, G., El-Deiry, W. S., Golstein, P., Peter, M. E., Vaux, D., Vandenabeele, P., Zhivotovsky, B., Blagosklonny, M. V., Malorni, W., Knight, R. A., et al. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401724 · Cited by 843

Cancer--A Biological Approach: I. The Processes Of Control. II. The Significance of Somatic Mutation

Burnet, M. (1957) · BMJ · doi:10.1136/bmj.1.5022.779 · Cited by 811

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

North, R. J. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.155.4.1063 · Cited by 657

Immunotherapy and chemotherapy — a practical partnership

Lake, R., & Robinson, B. W. S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1613 · Cited by 649

Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells

Galon, J., Franchimont, D., Hiroi, N., Frey, G., Boettner, A., Ehrhart-Bornstein, M., O’shea, J. J., Chrousos, G. P., & Bornstein, S. R. (2002) · The FASEB Journal · doi:10.1096/fj.01-0245com · Cited by 606

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

Apétoh, L., Ghiringhelli, F., Tesnière, A., Criollo, A., Ortiz, C., Lidereau, R., Mariette, C., Chaput, N., Mira, J. P., Delaloge, S., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00573.x · Cited by 604

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling

Paulos, C. M., Wrzesinski, C., Kaiser, Hinrichs, C. S., Chieppa, M., Cassard, L., Palmer, D. C., Boni, A., Muranski, P., Yu, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32205 · Cited by 586

Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes

Garnett‐Benson, C., Palena, C., Chakarborty, M., Tsang, K.-Y., Schlom, J., & Hodge, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1525 · Cited by 557

Decreased tumor surveillance in perforin-deficient mice.

van den Broek, M. F., Kägi, D., OSSENDORP, F. A., Toes, R. E. M., Vamvakas, S. M., Lutz, W. K., Melief, C. J. M., Zinkernagel, R. M., & Hengartner, H. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.5.1781 · Cited by 552

Homeostasis-Stimulated Proliferation Drives Naive T Cells to Differentiate Directly into Memory T Cells

Cho, B. K., Rao, V. P., Ge, Q., Eisen, H. N., & Chen, J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.549 · Cited by 509

Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis

Obeid, M., Panaretakis, T., Joza, N., Tufi, R., Tesniere, A., van Endert, P., Zitvogel, L., & Kroemer, G. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402201 · Cited by 474

Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial

Panici, P. B., Maggioni, A., Hacker, N. F., Landoni, F., Ackermann, S., Campagnutta, E., Tamussino, K. F., Winter, R., Pellegrino, A., Greggi, S., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji102 · Cited by 465

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells

Nowak, A. K., Lake, R. A., Marzo, A. L., Scott, B., Heath, W. R., Collins, E. J., Frelinger, J. A., & Robinson, B. W. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4905 · Cited by 463

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

Machiels, J.-P., Reilly, R. T., Emens, L. A., Ercolini, A. M., Lei, R. Y., Weintraub, D., Okoye, F. I., & Jaffee, E. M. (2001) · PubMed · Cited by 455

Demographic variations in the rising incidence of esophageal adenocarcinoma in white males

Bollschweiler, E., Wolfgarten, E., Gutschow, C. A., & H�lscher, A. H. (2001) · Cancer · doi:10.1002/1097-0142(20010801)92:3 · Cited by 452

Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer

Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444

External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing

Chakraborty, M., Abrams, S. I., Coleman, C. N., Camphausen, K. A., Schlom, J., & Hodge, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0073 · Cited by 435

B cells inhibit induction of T cell-dependent tumor immunity

Qin, Z., Richter, G. H. S., Schüler, T., Ibe, S., Cao, X., & Blankenstein, T. J. F. (1998) · Nature Medicine · doi:10.1038/nm0598-627 · Cited by 418

Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.

Nowak, A. K., Robinson, B. W. S., & Lake, R. (2003) · PubMed · Cited by 414

A novel dendritic cell subset involved in tumor immunosurveillance

Taı̈eb, J., Chaput, N., Menard, C., Apétoh, L., Ullrich, E., Bonmort, M., Péquignot, M. O., Casares, N., Terme, M., Flament, C., et al. (2006) · Nature Medicine · doi:10.1038/nm1356 · Cited by 403

Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination

Badovinac, V. P., Messingham, K. N., Jabbari, A., Haring, J. S., & Harty, J. T. (2005) · Nature Medicine · doi:10.1038/nm1257 · Cited by 403

Bortezomib enhances dendritic cell (DC)–mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications

Spisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2007) · Blood · doi:10.1182/blood-2006-10-054221 · Cited by 388

Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?

Muranski, P. J., Boni, A., Wrzesinski, C., Citrin, D. E., Rosenberg, S. A., Childs, R. W., & Restifo, N. P. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0666 · Cited by 358

“Of mice and men”

Kelland, L. R. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.028 · Cited by 352

Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells

Binder, R. J., & Srivastava, P. K. (2005) · Nature Immunology · doi:10.1038/ni1201 · Cited by 302

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

Borg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21102 · Cited by 302

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

Seggewiss, R. (2004) · Blood · doi:10.1182/blood-2004-07-2527 · Cited by 290

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

Arlen, P. M., Gulley, J. L., Parker, C., Skarupa, L., Pazdur, M. P., Panicali, D., Beetham, P. K., Tsang, K. Y., Grosenbach, D. W., Feldman, J. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2059 · Cited by 287

Primary Tumor Tissue Lysates Are Enriched in Heat Shock Proteins and Induce the Maturation of Human Dendritic Cells

Somersan, S., Larsson, M., Fonteneau, J., Basu, S., Srivastava, P. K., & Bhardwaj, N. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.4844 · Cited by 259

Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.

Berd, D., Maguire, H. C., Jr., & Mastrangelo, M. J. (1986) · PubMed · Cited by 251

Antibodies, Fc receptors and cancer

Nimmerjahn, F., & Ravetch, J. V. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.01.005 · Cited by 241

Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2?-deoxycytidine treatment

Serrano, A., Tanzarella, S., Lionello, I., Méndez, R., Traversari, C., Ruiz‐Cabello, F., & Garrido, F. (2001) · International Journal of Cancer · doi:10.1002/ijc.1452 · Cited by 239

Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy.

Nowak, A. K., Robinson, B. W. S., & Lake, R. (2002) · PubMed · Cited by 238

Effect of Cyclophosphamide on Immunological Control Mechanisms

Turk, J. L., & Parker, D. (1982) · Immunological Reviews · doi:10.1111/j.1600-065x.1982.tb00429.x · Cited by 237

Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

Atzpodien, J., Kirchner, H. H., Udo Jonas, A., Bergmann, L., Schott, H., Heynemann, H., Fornara, P., Loening, S. A., Roigas, J., Müller, S. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.155 · Cited by 223

Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells

Wrzesinski, C., Paulos, C. M., Gattinoni, L., Palmer, D. C., Kaiser, A., Yu, Z., Rosenberg, S. A., & Restifo, N. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30414 · Cited by 203

Ecto‐calreticulin in immunogenic chemotherapy

Obeid, M., Tesniere, A., Panaretakis, T., Tufi, R., Joza, N., Van Endert, P., Ghiringhelli, F., Apetoh, L., Chaput, N., Flament, C., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00567.x · Cited by 202

Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer

Schiavoni, G., Mattei, F., Pucchio, T. D., Santini, S. M., Bracci, L., Belardelli, F., & Proietti, E. (2000) · Blood · doi:10.1182/blood.v95.6.2024 · Cited by 196

Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma

Lech‐Marańda, E. (2004) · Blood · doi:10.1182/blood-2003-06-1850 · Cited by 187

Antivascular therapy of cancer: DMXAA

Baguley, B. C. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01018-0 · Cited by 187

Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas

PLATE, J. M. D., Plate, A. E., Shott, S., Bograd, S., & Harris, J. E. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0638-1 · Cited by 176

Antigen Concentration and Precursor Frequency Determine the Rate of CD8+ T Cell Tolerance to Peripherally Expressed Antigens

Morgan, D. J. W., Kreuwel, H. T. C., & Sherman, L. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.2.723 · Cited by 173

Chemo-Immunotherapy of Metastatic Colorectal Carcinoma With Gemcitabine Plus FOLFOX 4 Followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Induces Strong Immunologic and Antitumor Activity in Metastatic Colon Cancer Patients

Correale, P., Cusi, M. G., Tsang, K. Y., Vecchio, M. T. D., Marsili, S., Placa, M. L., Intrivici, C., Aquino, A., Micheli, L., Nencini, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.147 · Cited by 171

Tumor Antigens are Constitutively Presented in the Draining Lymph Nodes

Marzo, A. L., Lake, R., Lo, D. D., Sherman, L. A., McWilliam, A., Nelson, D. J., Robinson, B. W. S., & Scott, B. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5838 · Cited by 170

The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axis

Roberts, Z. J., Goutagny, N., Perera, P., Kato, H., Kumar, H., Kawai, T., Akira, S., Savan, R., Echo, D. V., Fitzgerald, K. A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061845 · Cited by 167

Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.

Berd, D., & Mastrangelo, M. J. (1988) · PubMed · Cited by 167

DNA Methylation Inhibitors in the Treatment of Leukemias, Myelodysplastic Syndromes and Hemoglobinopathies: Clinical Results and Possible Mechanisms of Action

Lübbert, M. (2000) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-59696-4_9 · Cited by 167

Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy

Gribben, J. G., Ryan, D. P., Boyajian, R. N., Urban, R. G., Hedley, M. L., Beach, K. J., Nealon, P., Matulonis, U. A., Campos, S. M., Gilligan, T. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2111 · Cited by 165

Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

Keilholz, U., Punt, C. J. A., Gore, M. E., Kruit, W. H. J., Patel, P., Líénard, D., Thomas, J., Proebstle, T. M., Schmittel, A. H., Schadendorf, D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.202 · Cited by 165

Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors

Rožková, D., Horváth, R., Bartůňková, J., & Špíšek, R. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.04.567 · Cited by 164

Late and persistent up-regulation of intercellular adhesion molecule-1 (ICAM-1) expression by ionizing radiation in human endothelial cells in vitro

Gaugler, M. (1997) · International Journal of Radiation Biology · doi:10.1080/095530097143428 · Cited by 164

Enhancing the Effect of THERATOPE STn-KLH Cancer Vaccine in Patients with Metastatic Breast Cancer by Pretreatment with Low-Dose Intravenous Cyclophosphamide

MacLean, G. D., Miles, D. W., Rubens, R. D., Reddish, M. A., & Longenecker, B. M. (1996) · Journal of Immunotherapy · doi:10.1097/00002371-199607000-00006 · Cited by 161

CpG Oligodeoxynucleotide Enhances Tumor Response to Radiation

Milas, L., Mason, K. A., Ariga, H., Hunter, N. R., Neal, R. E., Valdecanas, D. R., Krieg, A. Μ., & Whisnant, J. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0926 · Cited by 151

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects

Weiner, H. L., & Cohen, J. A. (2002) · Multiple Sclerosis Journal · doi:10.1191/1352458502ms790oa · Cited by 148

The immunological effects of taxanes

Chan, O. T. M., & Yang, L. (2000) · Cancer Immunology Immunotherapy · doi:10.1007/s002620000122 · Cited by 148

Activation of Tumor-Associated Macrophages by the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid Induces an Effective CD8+ T-Cell–Mediated Antitumor Immune Response in Murine Models of Lung Cancer and Mesothelioma

Jassar, A. S., Suzuki, E., Kapoor, V., Sun, J., Silverberg, M. B., Cheung, L., Burdick, M. D., Strieter, R. M., Ching, L., Kaiser, L. R., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1658 · Cited by 145

Immune Response Against Dying Tumor Cells

Zitvogel, L., Casares, N., Péquignot, M. O., Chaput, N., Albert, M. L., & Kroemer, G. (2004) · Advances in immunology · doi:10.1016/s0065-2776(04)84004-5 · Cited by 137

One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit Metastases

Grünhagen, D. J., Brunstein, F., Graveland, W. J., van Geel, A. N., de Wilt, J. H. W., & Eggermont, A. M. M. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000146147.89667.ed · Cited by 126

FASL –844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer

Sun, T., Zhou, Y., Li, H., Han, X., Shi, Y., Wang, L., Miao, X., Tan, W., Zhao, D., Zhang, X., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050707 · Cited by 125

Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments

Ge, Q., Hu, H., Eisen, H. N., & Chen, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052714099 · Cited by 121

Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice.

Glaser, M. (1979) · The Journal of Experimental Medicine · doi:10.1084/jem.149.3.774 · Cited by 119

Paclitaxel Enhances Macrophage IL-12 Production in Tumor-Bearing Hosts Through Nitric Oxide

Mullins, D. W., Burger, C. J., & Elgert, K. D. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.11.6811 · Cited by 116

Inhibitory Effect of Toll-Like Receptor 4 on Fusion between Phagosomes and Endosomes/Lysosomes in Macrophages

Shiratsuchi, A., Watanabe, I., Takeuchi, O., Akira, S., & Nakanishi, Y. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2039 · Cited by 112

Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma

Bajetta, E., Vecchio, M. D., Nova, P., Fusi, A., Daponte, A., Sertoli, M. R., Queirolo, P., Taveggia, P., Bernengo, M. G., Legha, S. S., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl007 · Cited by 112

Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer.

Yu, B., Kusmartsev, S. A., Cheng, F., Paolini, M., Nefedova, Y., Sotomayor, E. M., & Gabrilovich, D. I. (2003) · PubMed · Cited by 104

Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.

Thom, A. K., Alexander, H. R., Andrich, M. P., Barker, W. C., Rosenberg, S. A., & Fraker, D. L. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.264 · Cited by 103

Combination of Imatinib Mesylate with Autologous Leukocyte-Derived Heat Shock Protein and Chronic Myelogenous Leukemia

Li, Z., Qiao, Y., Liu, B., Laska, E. J., Chakravarthi, P., Kulko, J. M., Bona, R., Fang, M., Hegde, U. P., Moyo, V. M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0250 · Cited by 103

Cancer Immunologists and Cancer Biologists: Why We Didn't Talk Then but Need to Now

Prendergast, G. C., & Jaffee, E. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4626 · Cited by 102

Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.

Mattiuzzi, G. N., Cortes, J. E., Talpaz, M., Reuben, J. M., Rios, M. B., Shan, J., Kontoyiannis, D. P., Giles, F. J., RAAD, I. I., Verstovšek, S., et al. (2003) · PubMed · Cited by 101

Immunotherapy for human cancer using heat shock protein-peptide complexes

Srivastava, P. K. (2005) · Current Oncology Reports · doi:10.1007/s11912-005-0035-8 · Cited by 98

Cellular Immunity in Breast Cancer Patients Completing Taxane Treatment

Carson, W. E., Shapiro, C. L., Crespin, T. R., Thornton, L. M., & Andersen, B. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1016-03 · Cited by 94

Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice.

Orsini, F. R., Pavelić, Z. P., & Mihich, E. (1977) · PubMed · Cited by 85

Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: evidence for different susceptibility of IL-2– versus IL-15–activated NK cells

Chiossone, L., Vitale, C., Cottalasso, F., Moretti, S., Azzarone, B. G., Moretta, L., & Mingari, M. C. (2007) · Blood · doi:10.1182/blood-2006-07-037846 · Cited by 81

Polymorphisms of interleukin (IL)-1α, IL-1β, IL-6, IL-10, and IL-18 and the risk of ovarian cancer

Bushley, A. W., Ferrell, R. E., McDuffie, K., Terada, K. Y., Carney, M. E., Thompson, P. J., Wilkens, L. R., Tung, K., Ness, R. B., & Goodman, M. T. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.08.024 · Cited by 76

Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells

Galetto, A., Buttiglieri, S., Forno, S., Moro, F., Mussa, A., & Matera, L. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200311000-00010 · Cited by 73

Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections

Mumprecht, S., Matter, M. S., Pavelic, V., & Ochsenbein, A. F. (2006) · Blood · doi:10.1182/blood-2006-04-018705 · Cited by 70

Efficacy of GM-CSF-producing Tumor Vaccine after Docetaxel Chemotherapy in Mice Bearing Established Lewis Lung Carcinoma

Chu, Y., Wang, L.-X., Yang, G., Ross, H. J., Urba, W. J., Prell, R. A., Jooss, K. U., Xiong, S., & Hu, H. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199198.43587.ba · Cited by 69

Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor‐specific antitumor effect in vivo

Tanaka, F., Yamaguchi, H., Ohta, M., Mashino, K., Sonoda, H., Sadanaga, N., Inoue, H., & Mori, M. (2002) · International Journal of Cancer · doi:10.1002/ijc.10597 · Cited by 68

Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy

Behr, T. M., Memtsoudis, S. G., Sharkey, R. M., Blumenthal, R. D., Dunn, R. M., Gratz, S., Wieland, E., Nebendahl, K., Schmidberger, H., Goldenberg, D. M., et al. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980831)77:5 · Cited by 67

Lymphopenia: A new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma

Claude, L., Pérol, D., Ray-Coquard, I. L., Petit, T., Blay, J., Carrié, C., & Bachelot, T. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2005.06.004 · Cited by 61

Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients

Noguchi, M., Itoh, K., Yao, A., Mine, T., Yamada, A., Obata, Y., Furuta, M., Harada, M., Suekane, S., & Matsuoka, K. (2004) · The Prostate · doi:10.1002/pros.20157 · Cited by 58

Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines.

Nigam, A., Yacavone, R. F., ZAHURAK, M. L., Johns, C. M., Pardoll, D. M., Piantadosi, S., Levitsky, H. I., & Nelson, W. G. (1998) · International Journal of Oncology · doi:10.3892/ijo.12.1.161 · Cited by 58

Immunomodulation of Natural Killer Cell Activity by Flavone Acetic Acid: Occurrence Via Induction of Interferon /beta

Hornung, R. L., Young, H. A., Urba, W. J., & Wiltrout, R. H. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.15.1226 · Cited by 56

Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice.

Kozar, K., Kamiński, R., Świtaj, T., Ołdak, T., Machaj, E. K., Wysocki, P. J., Mackiewicz, A. A., Lasek, W., Jakóbisiak, M., & Gołąb, J. (2003) · PubMed · Cited by 45

Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients.

Arinaga, S., Akiyoshi, T., & Tsuji, H. (1986) · PubMed · Cited by 44

5-Fluorouracil–Based Chemotherapy Enhances the Antitumor Activity of a Thymidylate Synthase–Directed Polyepitopic Peptide Vaccine

Correale, P., Vecchio, M. T. D., Genova, G. D., Savellini, G. G., Placa, M. L., Terrosi, C., Vestri, M., Urso, R., Lemonnier, F. A., Aquino, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji188 · Cited by 43

Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

D. –. G. C. R. C. C. T. G., Atzpodien, J., Kirchner, H. H., Rebmann, U., Soder, M., Gertenbach, U., Siebels, M., Roigas, J., Raschke, R., Salm, S., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603271 · Cited by 42

Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer

Gomez, G. G., Hutchison, R., & Kruse, C. A. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2001.0222 · Cited by 35

Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms

Levitt, M. L., Kassem, B. E. B., Gooding, W. E., Miketic, L. M., Landreneau, R. J., Ferson, P. F., Keenan, R., Yousem, S. A., Lindberg, C., Trenn, M. R., et al. (2003) · Lung Cancer · doi:10.1016/j.lungcan.2003.09.011 · Cited by 31

Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non‐small cell lung cancer

Ishida, A., Miyazawa, T., Miyazu, Y., Iwamoto, Y., Zaima, M., Kanoh, K., Sumiyoshi, H., & Masao, D. O. I. (2006) · Respirology · doi:10.1111/j.1440-1843.2006.00790.x · Cited by 30

Influence of longterm therapy with methotrexate and low dose corticosteroids on type 1 and type 2 cytokine production in CD4+ and CD8+ T lymphocytes of patients with rheumatoid arthritis.

Schuerwegh, A. J., Offel, J. F. V., Bridts, C. H., Stevens, W. J., & Clerck, L. S. D. (2001) · PubMed · Cited by 23

Effect of radiation on the expression of carcinoembryonic antigen on the membranes of human gastric adenocarcinoma cells--immunological study using monoclonal antibodies.

Hareyama, M., Imai, K., Ban, T., Koshiba, H., Kubo, K., Shidou, M., Oouchi, A., & Morita, K. (1988) · PubMed · Cited by 8

Phase I Study of Low-Dose Interleukin-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia

Kasamon, Y. L., Flinn, I. W., Grever, M. R., Diehl, L. F., Garrett-Mayer, E. S., Goodman, S. N., Lucas, M. S., & Byrd, J. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1612 · Cited by 7

Short Communication: The Efficacy of Fixed Dose Rate Infusion of Gemcitabine Combined with IFN-α2a in Patients with Advanced Refractory Renal Cell Carcinoma

Massacesi, C., Burattini, L., Marcucci, F., & Bonsignori, M. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.165 · Cited by 6

Restoration of macrophage tumoricidal activity by bleomycin correlates with the decreased production of transforming growth factor ? in rats bearing KDH-8 hepatoma cells

Yuan, L., Kobayashi, M., Kuramitsu, Y., Li, Y., Matsushita, K., & Hosokawa, M. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050404 · Cited by 6

Untitled work

(2001) · doi:10.1002/1521-4141(200108)31:8

Immunity, Inflammation, and Cancer

Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755

The immune contexture in human tumours: impact on clinical outcome

Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496

Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments

Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,023

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.67 · Cited by 951

Immune Effects of Conventional Cancer Therapeutics

Demaria, S., & Galluzzi, L. (2018) · Springer Publishing Company eBooks · doi:10.1891/9781617052736.0022

Activation of Immune-Mediated Tumor Cell Death by Chemotherapy

McCoy, M. J., Nowak, A. K., & Lake, R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_14

Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy

Hannani, D., Sistigu, A., Kepp, O., Galluzzi, L., Kroemer, G., & Zitvogel, L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325d4d · Cited by 88

Immunogenic effects of chemotherapy-induced tumor cell death

Wang, Y., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 328